Today's Veterinary Practice

JUL-AUG 2012

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link: http://todaysveterinarypractice.epubxp.com/i/75883

Contents of this Issue

Navigation

Page 87 of 91

JOURNAL CLUB DERMATOLOGY Treatment of Demodicosis in Dogs: 2011 Clinical Practice Guidelines Mueller RS, Bensignor E, Ferrer L, et al. Veterinary Dermatology 2012; 23(2):86-95. This article presents recent guidelines written by an international group of special- ists with the goal of providing veterinarians with current recommendations for the diagnosis and treatment of canine EFNPEJDPTJT 1VCMJTIFE TUVEJFT PG UIF WBSJPVT USFBUNFOU PQUJPOT XFSF SFWJFXFE BOE TVNNBSJ[FE %FNPEJDPTJT DBO VTVBMMZ CF EJBHOPTFE CZ EFFQ TLJO TDSBQJOHT PS USJDIPHSBNT BOE JO SBSF DBTFT CZ TLJO CJPQTZ *NNVOF TVQQSFTTJPO due to endoparasitism or malnutrition in young dogs and endocrine diseases, neoplasia, and chemotherapy in older EPHT BSF DPOTJEFSFE QSFEJTQPTJOH GBDUPST %PHT XJUI EJTFBTF TFWFSJUZ SFRVJSJOH QBSBTJUJDJEBM UIFSBQZ TIPVME OPU CF CSFE There is good evidence for the efficacy of weekly amitraz rinses and daily oral macrocyclic lactones, such as milbemycin oxime, ivermectin, and moxidectin for the treat- NFOU PG DBOJOF EFNPEJDPTJT 8FFLMZ BQQMJDBUJPO PG UPQJDBM moxidectin can be useful in dogs with milder forms of the disease. There is some evidence of the efficacy of weekly or twice weekly subcutaneous or oral doramectin. Secondary bacterial skin infections frequently complicate the disease and require antimicrobial therapy. Treatment should be monitored with monthly skin scrapings and extended beyond clinical and microscopic cure to minimize recurrence. Sandra Koch, DVM, MS, Diplomate ACVD, University of Minnesota To read the complete demodicosis treatment guidelines, go to onlinelibrary.wiley.com/doi/10.1111/j.1365-3164.2011.01026.x/full INFECTIOUS DISEASE Evaluation Of Orally Administered Famciclovir in Cats Experimentally Infected with Feline Herpesvirus Type-1 Thomasy SM, Lim CC, Reilly CM, et al. American Journal of Veterinary Research 2011; 72(1):85-95. The objective of this randomized, blinded, placebo-controlled study was to investigate the safety and efficacy of the antiviral agent famciclovir for the treatment of cats with experimentally induced feline herpesvirus type-1 (FHV-1). Famciclovir is the prodrug for penciclovir, a drug that has potent activity against FHV-1 JO WJUSP *O UIJT TUVEZ IFBMUIZ TQFDJGJD QBUIPHFO GSFF DBUT XFSF JOPDVMBUFE XJUI ')7 JOUSBOBTBMMZ BOE JOUP UIF conjunctiva; then received famciclovir (90 mg/kg PO) or placebo (lactulose) Q 8 H for 21 days. Severity of clinical signs (ocular discharge, nasal discharge, sneezing, blepharospasm, and conjunctivitis) was assessed daily. All cats developed signs consistent with active FHV-1 infection. Those treated with famciclovir had lower disease scores on days 4 to 18 and lower concentrations of anti–FHV-1 antibody and serum globulins than MBDUVMPTF USFBUFE DBUT *O BEEJUJPO DBUT USFBUFE XJUI GBNDJDMPWJS HBJOFE XFJHIU PWFS UIF USFBUNFOU QFSJPE XIJMF QMBDFCP treated cats lost weight during the first week. Further, ophthalmic variables (including severity of conjunctivitis on histopathology and goblet cell density) were more favorable in famciclovir-treated cats, although they did not return to normal by end of the study period. No adverse effects were associated with this dose or dura- tion of famciclovir treatment (as assessed by clinical evalu- ation and results of serum CBCs, serum biochemistry, and urinalysis). This study suggests that famciclovir administration in this fashion is safe and may be efficacious at ameliorating systemic, ophthalmic, clinicopathologic, virologic, and histo- logic manifestations of FHV-1 infection in cats. Further studies are needed to determine whether famciclovir is effective when initiated after clinical signs of viral infection appear. Claire R. Sharp, BSc, BVMS(Hons), MS, Diplomate ACVECC, Mississippi State University 86 Today's Veterinary Practice July/August 2012 CRITICAL POINTS r 'BNDJDMPWJS JT UIF QSPESVH GPS QFODJDMPWJS B ESVH that has potent activity against FHV-1 in vitro. r *O UIJT TUVEZ DBUT USFBUFE XJUI GBNDJDMPWJS BGUFS inoculation with FHV-1 has lower disease scores, lower concentrations of anti–FHV-1 antibody and serum globulins, and more favorable ophthalmic variables than placebo-treated cats. r 4UVEZ SFTVMUT TVHHFTU UIBU GBNDJDMPWJS NH LH 10 Q 8 H) is safe and may be efficacious at ameliorat- ing the manifestations of FHV-1 infection in cats. CRITICAL POINTS r 5IF HPBM PG UIJT BSUJDMF XBT UP QSPWJEF WFUFSJOBS- ians with current recommendations for the diag- nosis and treatment of canine demodicosis. r 5IFSF JT HPPE FWJEFODF GPS UIF FGGJDBDZ PG weekly amitraz rinses and daily oral macrocy- clic lactones, such as milbemycin oxime, iver- mectin, and moxidectin.

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - JUL-AUG 2012